Navigation Links
ERT Reports Second Quarter 2009 Results
Date:7/30/2009

11,002 4,435 19,925 7,891 Income tax provision 4,342 1,887 7,519 3,273 ----- ----- ----- ----- Net income $6,660 $2,548 $12,406 $4,618 ====== ====== ======= ====== Basic net income per share $0.13 $0.05 $0.24 $0.09 ===== ===== ===== ===== Diluted net income per share $0.13 $0.05 $0.24 $0.09 ===== ===== ===== ===== Shares used to calculate basic net income per share 50,734 48,866 50,686 49,872 ====== ====== ====== ====== Shares used to calculate diluted net income per share 52,182 49,175 52,038 50,169 ====== ====== ====== ====== eResearchTechnology, Inc. and Subsidiaries Consolidated Balance Sheets (in thousands, except share and per share amounts) December 31, June 30, 2008 2009 ------------ -------- ASSETS (unaudited) Current assets: Cash and cash equivalents $66,376 $68,729 Short-term investments 50 50 Investment in marketable securities - 816 Accounts receivable less allowance for doubtful accounts of $695 and $657, respectively 29,1
'/>"/>
SOURCE ERT
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
2. Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2009 Results
4. Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
5. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
6. Neurocrine Biosciences Reports Second Quarter 2009 Results
7. Sunesis Reports Financial Results for the Second Quarter 2009
8. Cynosure Reports Second Quarter 2009 Financial Results
9. NeoGenomics Reports Second Quarter 2009 Results
10. Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008s $2.65.
11. Neogen Reports 16% Increase in Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... Applying a well-known optical phenomenon called thin-film interference, ... demonstrated the ability to "paint" ultra-thin coatings onto ... for making future, flexible electronic devices, creating advanced ... rocket ships and spacecraft with extremely lightweight decorative ... water, it becomes iridescent, revealing a myriad of ...
(Date:9/30/2014)... of one of nature,s most efficient light-harvesting structures, ... by Alejandro Briseno of the University of Massachusetts ... long-sought polymer architecture to boost power-conversion efficiency of ... , Briseno, with colleagues and graduate students ... and Dresden University of Technology, Germany, report in ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... scientists observe a reaction moving at greater than 10 meters ... feat some would say is nearly impossible. But ... dynamic transmission electron microscope (DTEM). DTEM,s ability to ... it,s happening has earned it one of the 10 winning ...
... , Aug. 2 Octapharma USA today ... is the Rush Hemophilia & Thrombophilia Center at Rush ... focused on human protein therapies in hematology, immune therapy, intensive care and emergency ... Leonard A. ...
... Aug. 2 Tengion Inc. (Nasdaq: TNGN ... to the position of Chief Financial Officer.  Mr. Davis comes to Tengion ... technologies to develop improved protein therapeutics. At its peak, Neose employed 200 ... , , ...
Cached Biology Technology:Livermore's DTEM earns innovation award from Microscopy Today 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Tengion Appoints A. Brian Davis Chief Financial Officer 2
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... Smart Search & Match,the leading provider of high-performance ... has joined the company as Product Marketing Manager. ... 15 years of product and marketing management,experience to ... many high-tech products and solutions worldwide. He has ...
... the human body in ways never imagined only a ... population of patients who are newly susceptible to opportunistic ... formidable clinical opponent, and foremost among them is ... from ASM Press. "This volume has been ...
... of the global population living in cities reached 50 ... exciting new book series which brings together leading experts ... all over the world. The aim of the ... facing the architects, planners, developers and inhabitants of the ...
Cached Biology News:New text focuses on formidable opportunistic fungus 2Springer looks ahead to the Future City 2
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Polyclonal Antibody to PRG3...
Biology Products: